Ranitidine Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 75 mg, 150 mg, 300 mg
Reference Brands: Zantac(US & EU)- dis.contd in many markets
Category:
Medical Aid
Ranitidine tablets are H2 receptor antagonists that block histamine receptors in the stomach lining, reducing acid secretion. They provide relief from heartburn, GERD, ulcers, and acid indigestion, promote healing of ulcers, and prevent acid-related damage, improving comfort and preventing complications associated with excessive gastric acid.
Ranitidine tablets is available in Tablet
and strengths such as 75 mg, 150 mg, 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ranitidine tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ranitidine tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ranitidine tablets were widely used for acid-related disorders in the US and EU, supported by comprehensive regulatory dossiers demonstrating safety, efficacy, and manufacturing quality. However, due to concerns over NDMA impurities, many countries, including the US and EU, have withdrawn ranitidine products from the market. Regulatory authorities have implemented strict testing and monitoring protocols for existing stocks. For detailed information on regulatory status, dossiers, and licensing requirements for alternatives, visit Pharmatradz. Stay informed on the latest updates regarding the regulatory landscape for ranitidine and safe alternatives in global markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing